Broker Liberum has identified hVIVO PLC as one of its best investment ideas for 2023.
This is based on the company's strong performance in 2022, as highlighted in Wednesday's trading statement.
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) hailed a period of significant progress, including a major licensing agreement with Genmab (CSE:GEN) worth up to US$624mln per product, as it unveiled its interim results.
The deal, announced in October, will allow the US giant to develop and commercialise an anti-glycan monoclonal antibody. Scancell said it provided strong validation for its platform.
Ariana Resources PLC (AIM:AAU) said results from recent drilling at Salinbas in Turkey have confirmed the continuity of gold and silver mineralisation with another prospect at Ardala.
Assay results had been slow to come through because of a post-Covid rush at the laboratory, while wet weather also hampered drilling but progress overall is now speeding up, said the company.
88 Energy Ltd (AIM:88E, ASX:88E, OTC:EEENF) has told investors it expects to start drilling the Hickory-1 exploration well, within its Project Phoenix area, on or around 1 March this year.
The well, located in the area previously referred to by 88 Energy as ‘Icewine East’, is aimed at oil-bearing conventional reservoirs like those seen nearby by Pantheon Resources.
Greatland Gold PLC (AIM:GGP, OTC:GRLGF) said the development of the mine decline at its 30% joint venture Havieron has accelerated in recent weeks as ground conditions improved.
Havieron, in Western Australia, is being developed by partner and 70% owner Newcrest, which said the decline had reached a depth of 1,519 metres (m) as of 18 January 2023 after record rates of progress recently.
Contract research group hVIVO PLC said it is on track to post record revenues, while its underlying earnings (EBITDA) have exceeded expectations.
According to the company’s trading update, 2022 turnover will be in the order of £50.6mln, representing a 30% increase year-on-year.
Altech Chemicals Ltd (ASX:ATC) has made broad progress on the CERENERGY® battery joint venture (JV) with Fraunhofer IKTS, holding two expert workshops, selecting major equipment suppliers and engaging in early offtake discussions.
Late last year Altech announced that it had designed and launched the CERENERGY® SAS 60 kilowatt-hour battery pack (ABS60) for the renewable energy and grid storage market.
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has boosted its finances by A$6,219,241 after receiving two research and development (R&D) rebates.
This comprises A$4,311,202 from the Australian Tax Office for the year ending June 30, 2022, and an advance payment of A$1,908,039 from Radium Capital, as a proportion of the company’s 2023 financial year R&D applicable expenditure.